CareDx Inc
NASDAQ:CDNA
Operating Margin
CareDx Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
CareDx Inc
NASDAQ:CDNA
|
681.2m USD |
-14%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
371.4B USD |
31%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
156.3B USD | N/A | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
158.1B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
142.9B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.7B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
104.9B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
62.5B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
60.1B USD |
-7%
|
CareDx Inc
Glance View
CareDx Inc. is a vibrant player in the biotech landscape, navigating the intricate world of transplant medicine with a unique focus on precision diagnostics. Founded in 1998 and headquartered in South San Francisco, CareDx is deeply entrenched in the development of solutions that enhance the longevity and quality of life for organ transplant recipients. Their flagship offerings, such as AlloMap and AlloSure, are non-invasive, blood-based tests that provide critical insights into the functioning and health of transplanted organs. These tests are pivotal in assessing transplant recipients for possible organ rejection, thus presenting rapid, reliable data that may preempt irreversible damage. CareDx captures value by providing these sophisticated diagnostic tests and services to transplant centers that require cutting-edge technology to improve patient outcomes. Revenue generation for CareDx is anchored in its comprehensive commercial approach, developing partnerships with healthcare providers and transplant centers globally. By leveraging an innovative mixture of proprietary testing technology and patient-centric solutions, the company taps into the ongoing demand for improved post-transplant care. Their business model primarily revolves around offering subscription-based services that incorporate longitudinal patient monitoring and data analytics—providing healthcare professionals with a steady flow of actionable insights. CareDx further extends its revenue streams through patient management solutions and digital health offerings, enhancing its footprint in the growing transplant diagnostics market. Beyond diagnostics, CareDx's strategic aspirations see it expanding its portfolio into more integrated healthcare solutions, resonating with healthcare practitioners seeking more personalized and predictive transplant care.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on CareDx Inc's most recent financial statements, the company has Operating Margin of -14.4%.
You don't have any saved screeners yet